Organon & Co (OGN)
18.07
-0.71
(-3.78%)
USD |
NYSE |
Nov 01, 16:00
18.02
-0.05
(-0.28%)
After-Hours: 20:00
Organon Shareholders Equity (Quarterly): 493.00M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 493.00M |
| June 30, 2024 | 144.00M |
| March 31, 2024 | 48.00M |
| December 31, 2023 | -70.00M |
| September 30, 2023 | -589.00M |
| June 30, 2023 | -555.00M |
| March 31, 2023 | -737.00M |
| December 31, 2022 | -892.00M |
| Date | Value |
|---|---|
| September 30, 2022 | -1.066B |
| June 30, 2022 | -1.137B |
| March 31, 2022 | -1.25B |
| December 31, 2021 | -1.508B |
| September 30, 2021 | -1.618B |
| June 30, 2021 | -1.934B |
| March 31, 2021 | 4.722B |
| December 31, 2020 | 5.486B |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-1.934B
Minimum
Jun 2021
5.486B
Maximum
Dec 2020
-28.94M
Average
-663.00M
Median
Shareholders Equity (Quarterly) Benchmarks
| Eli Lilly and Co | 14.24B |
| Biomarin Pharmaceutical Inc | 5.413B |
| Cassava Sciences Inc | 188.97M |
| Ligand Pharmaceuticals Inc | 775.20M |
| TG Therapeutics Inc | 177.57M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 12.75B |
| Total Liabilities (Quarterly) | 12.26B |
| Debt to Equity Ratio | 17.75 |
| Current Ratio | 1.705 |
| Net Debt Paydown Yield | -0.08% |